

Accepted Manuscript

Title: Effect of montelukast in experimental model of Parkinson's disease

Authors: Vetrivel Babu Nagarajan, Padmaja Anil Marathe


PII: S0304-3940(18)30403-8
DOI: <https://doi.org/10.1016/j.neulet.2018.05.052>
Reference: NSL 33631

To appear in: *Neuroscience Letters*

Received date: 8-2-2018
Revised date: 20-4-2018
Accepted date: 31-5-2018

Please cite this article as: Vetrivel Babu Nagarajan, Padmaja Anil Marathe, Effect of montelukast in experimental model of Parkinson's disease, *Neuroscience Letters* <https://doi.org/10.1016/j.neulet.2018.05.052>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title Page

Type of article: Original Research Article

Running title: Montelukast in Parkinson's Disease

Title of the article: Effect of montelukast in experimental model of Parkinson's disease

¹ Dr. Vetrivel Babu Nagarajan ,² Dr. Padmaja Anil Marathe

Name Dr. Vetrivel Babu Nagarajan, **Email** vetrivelbabu@gmail.com ,**Academic Qualification** Post Graduate Resident, MD Pharmacology, Department of Pharmacology & Therapeutics, **Affiliation** Seth GS Medical College, KEM Hospital, Mumbai ,

Dr. Padmaja Anil Marathe, **Email** pam2671@gmail.com, **Academic Qualification** Professor (Additional), MD Pharmacology, Department of Pharmacology & Therapeutics. **Affiliation** Seth GS Medical College, KEM Hospital, Mumbai.

Highlights:

- Montelukast reduced the oxidative and inflammatory markers in rotenone model of Parkinson's disease
- Montelukast had a protective action against rotenone induced Parkinson's disease
- Relatively higher dose of montelukast had better protective action

Abstract:

Despite the availability of many drugs offering symptomatic relief in Parkinson's disease, there are no drugs available offering neuroprotective effect. Hence, it was decided to evaluate the neuroprotective effect of montelukast, an anti-inflammatory drug, in rotenone induced model of Parkinson's disease in rats. 48 male wistar rats were randomly divided into three groups. Group 1: Vehicle control, Group 2: Montelukast 5mg/kg, Group 3: Montelukast 10mg/kg. All the groups received rotenone 2.5mg/kg intraperitoneally for 10 days as a disease inducing agent. The study drug montelukast was administered to respective groups orally from day 11 to day 24. On day 25, 24 hours after 14 days of study drug administration,

Download English Version:

<https://daneshyari.com/en/article/8841409>

Download Persian Version:

<https://daneshyari.com/article/8841409>

[Daneshyari.com](https://daneshyari.com)